Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $101.24M by Medicaid between Jan 2018 and Dec 2024, across 382 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
DOWNEY, CA 90242
DOWNEY, CA 90242
33aNPI1518012301assigned 01/24/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$101.24M
24GClaims2,390,781
24DCodes billed382
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#21 of 410
Median peer was paid$6.90M
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 183,830 | $898K | |
| 2019 | 298,915 | $12.09M | |
| 2020 | 269,369 | $18.08M | |
| 2021 | 298,962 | $13.99M | |
| 2022 | 387,200 | $17.15M | |
| 2023 | 462,709 | $17.94M | |
| 2024incomplete | 489,796 | $21.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 77,186 | 72,226 | $33.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 20,192 | 19,230 | $16.54M |
| G0378 | Hospital observation service, per hour | 13% | 13,906 | 8,438 | $13.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 13,482 | 13,211 | $3.98M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 1,803 | 1,774 | $2.12M |
| 0450 | Emergency room services | 1.5% | 57,595 | 52,611 | $1.56M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 7,308 | 7,197 | $1.50M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.4% | 1,582 | 1,530 | $1.45M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 15,172 | 14,741 | $1.41M |
| 71045 | Radiologic examination, chest; single view | 1.3% | 29,022 | 27,423 | $1.36M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,880 | 5,793 | $959K |
| 59025 | Fetal non-stress test | <1% | 4,665 | 1,892 | $947K |
370 more codes
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 10,311 | $810K |
| 76830 | Ultrasound, transvaginal | <1% | 9,703 | $770K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 9,467 | $740K |
| 76818 | <1% | 7,872 | $687K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 560 | $635K |
| 86885 | <1% | 8,669 | $598K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 23,072 | $554K |
| 86900 | <1% | 12,725 | $550K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,695 | $543K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,306 | $512K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,684 | $507K |
| 93971 | <1% | 2,587 | $435K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,864 | $408K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,780 | $367K |
| 77080 | <1% | 3,241 | $363K | |
| 83880 | <1% | 17,422 | $351K | |
| 76770 | <1% | 3,588 | $329K | |
| 80051 | <1% | 127,165 | $322K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,570 | $306K |
| 76641 | <1% | 3,223 | $303K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,592 | $301K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 116,602 | $293K |
| 47562 | <1% | 79 | $285K | |
| 82565 | <1% | 130,929 | $264K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,405 | $257K |
| 76536 | <1% | 2,563 | $248K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,612 | $241K |
| 84702 | <1% | 37,367 | $239K | |
| 74183 | <1% | 533 | $213K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,968 | $201K |
| 70491 | <1% | 1,009 | $195K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,758 | $192K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,768 | $192K |
| 74178 | <1% | 434 | $190K | |
| 86923 | <1% | 1,540 | $189K | |
| 71250 | <1% | 1,539 | $188K | |
| 70496 | <1% | 825 | $185K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 12,131 | $185K |
| 76801 | <1% | 2,839 | $183K | |
| 86901 | <1% | 12,740 | $169K | |
| 70498 | <1% | 746 | $165K | |
| 93970 | <1% | 688 | $164K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,071 | $156K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,284 | $149K |
| 70486 | <1% | 1,507 | $148K | |
| 72141 | <1% | 732 | $146K | |
| 87505 | <1% | 1,702 | $146K | |
| 73630 | <1% | 3,202 | $146K | |
| 84460 | <1% | 59,731 | $141K | |
| 73030 | <1% | 2,788 | $140K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,116 | $140K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,360 | $139K |
| 76870 | <1% | 1,768 | $135K | |
| 93017 | <1% | 387 | $134K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,884 | $133K |
| 72100 | <1% | 1,677 | $131K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,060 | $128K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,167 | $128K |
| 84520 | <1% | 112,907 | $125K | |
| 73610 | <1% | 2,955 | $125K | |
| 73562 | <1% | 2,483 | $122K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,284 | $121K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,121 | $119K |
| 82247 | <1% | 55,737 | $114K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,068 | $107K |
| 76881 | <1% | 1,082 | $106K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 480 | $105K |
| 82947 | <1% | 100,408 | $103K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,179 | $99K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,080 | $96K |
| 0637 | <1% | 164,576 | $95K | |
| 84075 | <1% | 50,846 | $95K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,121 | $91K |
| 84484 | <1% | 40,776 | $87K | |
| 85610 | <1% | 60,970 | $87K | |
| 73130 | <1% | 1,966 | $84K | |
| 99199 | Unlisted special service, procedure or report | <1% | 2,883 | $82K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,261 | $82K |
| 80061 | Lipid panel | <1% | 6,830 | $80K |
| 77065 | Tomosynthesis, mammo | <1% | 895 | $80K |
| 85027 | <1% | 16,787 | $78K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 498 | $78K |
| 73560 | <1% | 1,522 | $74K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 45,798 | $74K |
| 84450 | <1% | 45,697 | $74K | |
| 83690 | <1% | 40,200 | $71K | |
| 73502 | <1% | 1,262 | $70K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,506 | $69K |
| 0250 | <1% | 17,370 | $69K | |
| 74018 | <1% | 1,406 | $64K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,638 | $62K |
| 73110 | <1% | 1,391 | $58K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,171 | $57K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,794 | $54K |
| P9021 | Red blood cells, each unit | <1% | 1,196 | $53K |
| 76380 | <1% | 771 | $52K | |
| 90674 | <1% | 3,880 | $48K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,696 | $46K |
| 83970 | <1% | 1,179 | $44K | |
| 82310 | <1% | 18,375 | $42K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,803 | $42K |
| 73221 | <1% | 189 | $42K | |
| 87040 | <1% | 19,261 | $41K | |
| 93880 | <1% | 120 | $41K | |
| 73080 | <1% | 934 | $41K | |
| 81003 | <1% | 60,515 | $40K | |
| 73140 | <1% | 985 | $40K | |
| 86141 | <1% | 6,233 | $40K | |
| 83735 | <1% | 18,411 | $39K | |
| 82728 | <1% | 3,617 | $39K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,042 | $38K |
| 82248 | <1% | 31,040 | $37K | |
| 87088 | <1% | 16,776 | $36K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 251 | $36K |
| Z7502 | <1% | 1,570 | $35K | |
| 72040 | <1% | 687 | $35K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,766 | $35K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 391 | $34K |
| 72197 | <1% | 84 | $34K | |
| 73590 | <1% | 658 | $33K | |
| 86780 | <1% | 3,094 | $32K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13,519 | $32K |
| 80076 | <1% | 4,469 | $32K | |
| 74174 | <1% | 78 | $31K | |
| 73100 | <1% | 409 | $29K | |
| 86803 | <1% | 2,664 | $28K | |
| 82607 | <1% | 2,535 | $28K | |
| 83605 | <1% | 11,879 | $27K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13,959 | $27K |
| 73090 | <1% | 605 | $26K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,646 | $25K |
| 72131 | <1% | 183 | $25K | |
| 85379 | <1% | 5,637 | $24K | |
| 0258 | <1% | 7,787 | $23K | |
| J3490 | Unclassified drugs | <1% | 12,868 | $22K |
| 83550 | <1% | 3,135 | $22K | |
| 87340 | <1% | 3,154 | $21K | |
| 81513 | <1% | 268 | $21K | |
| 80306 | <1% | 3,446 | $21K | |
| 90686 | <1% | 2,541 | $21K | |
| 73120 | <1% | 203 | $20K | |
| 87449 | <1% | 2,759 | $20K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,846 | $20K |
| 87210 | <1% | 6,136 | $20K | |
| 78306 | <1% | 55 | $20K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 581 | $19K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,957 | $19K |
| 97161 | <1% | 2,034 | $18K | |
| 77072 | <1% | 172 | $18K | |
| 84100 | <1% | 11,301 | $17K | |
| 73564 | <1% | 156 | $17K | |
| 82077 | <1% | 4,315 | $17K | |
| 99499 | <1% | 733 | $17K | |
| 88342 | <1% | 116 | $17K | |
| 82040 | <1% | 6,183 | $16K | |
| 82746 | <1% | 1,583 | $16K | |
| 84146 | <1% | 797 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,210 | $16K |
| 83540 | <1% | 3,178 | $16K | |
| 71101 | <1% | 154 | $16K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,331 | $15K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 149 | $15K |
| 82570 | <1% | 2,922 | $14K | |
| 82043 | <1% | 2,390 | $14K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 755 | $14K |
| 87324 | <1% | 1,604 | $14K | |
| 87481 | <1% | 599 | $14K | |
| 0710 | <1% | 2,366 | $13K | |
| 72050 | <1% | 100 | $13K | |
| 83520 | <1% | 832 | $12K | |
| J1815 | Injection, insulin, per 5 units | <1% | 7,651 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,184 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 769 | $12K |
| 85730 | <1% | 3,957 | $12K | |
| 96367 | <1% | 1,126 | $11K | |
| 84439 | <1% | 2,048 | $11K | |
| 80179 | <1% | 2,561 | $11K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,044 | $11K |
| 85652 | <1% | 6,441 | $11K | |
| 84132 | <1% | 4,035 | $11K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,192 | $10K |
| 73660 | <1% | 168 | $10K | |
| 83001 | <1% | 508 | $10K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 269 | $10K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,535 | $9K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,322 | $9K |
| 84156 | <1% | 2,492 | $8K | |
| 72070 | <1% | 82 | $8K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,631 | $8K |
| G0008 | Administration of influenza virus vaccine | <1% | 3,151 | $8K |
| 72081 | <1% | 133 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,053 | $8K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,859 | $8K |
| 86480 | <1% | 136 | $8K | |
| 0370 | <1% | 2,320 | $8K | |
| 77061 | <1% | 75 | $8K | |
| 82550 | <1% | 3,263 | $8K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,018 | $7K |
| 74170 | <1% | 26 | $7K | |
| 84295 | <1% | 1,667 | $7K | |
| 87081 | <1% | 3,477 | $7K | |
| 87536 | <1% | 83 | $7K | |
| 87205 | <1% | 3,122 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,591 | $7K |
| 86880 | <1% | 156 | $6K | |
| 73060 | <1% | 106 | $6K | |
| 90656 | <1% | 733 | $6K | |
| 82962 | <1% | 4,610 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,915 | $6K |
| 86704 | <1% | 913 | $6K | |
| 86787 | <1% | 413 | $5K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 44 | $5K |
| 84550 | <1% | 1,961 | $5K | |
| 86762 | <1% | 354 | $5K | |
| 72170 | <1% | 42 | $5K | |
| 73200 | <1% | 40 | $5K | |
| 80164 | <1% | 450 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,898 | $5K |
| 83615 | <1% | 1,562 | $5K | |
| 87186 | <1% | 2,286 | $5K | |
| 84145 | <1% | 1,587 | $5K | |
| 73700 | <1% | 37 | $5K | |
| 84403 | <1% | 172 | $5K | |
| 82627 | <1% | 203 | $5K | |
| 44970 | <1% | 54 | $5K | |
| 90715 | <1% | 303 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,159 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 958 | $4K |
| 86317 | <1% | 661 | $4K | |
| 97116 | <1% | 1,084 | $4K | |
| 84165 | <1% | 382 | $4K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,453 | $4K |
| 0255 | <1% | 762 | $4K | |
| 73070 | <1% | 59 | $4K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,866 | $4K |
| 87631 | <1% | 295 | $4K | |
| 90662 | <1% | 597 | $3K | |
| 86665 | <1% | 197 | $3K | |
| 87070 | <1% | 991 | $3K | |
| 86038 | <1% | 354 | $3K | |
| 82140 | <1% | 626 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,153 | $3K |
| 72146 | <1% | 13 | $3K | |
| 73522 | <1% | 25 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 3,089 | $3K |
| 74240 | <1% | 16 | $3K | |
| 74181 | <1% | 13 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 312 | $3K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,080 | $3K |
| 70544 | <1% | 13 | $3K | |
| 84153 | <1% | 172 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 647 | $2K |
| 86765 | <1% | 201 | $2K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 49 | $2K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,312 | $2K |
| 80162 | <1% | 198 | $2K | |
| 83721 | <1% | 257 | $2K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 450 | $2K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 241 | $2K |
| 82105 | <1% | 143 | $2K | |
| 82670 | <1% | 67 | $2K | |
| 74220 | <1% | 12 | $2K | |
| 86364 | <1% | 157 | $2K | |
| 74230 | <1% | 12 | $2K | |
| 81015 | <1% | 607 | $2K | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 319 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 26 | $2K |
| 88341 | <1% | 13 | $2K | |
| 85014 | <1% | 832 | $2K | |
| 10060 | <1% | 28 | $2K | |
| 86664 | <1% | 99 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,659 | $2K |
| 72110 | <1% | 12 | $1K | |
| 82977 | <1% | 168 | $1K | |
| 76706 | <1% | 25 | $1K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 1,408 | $1K |
| 86308 | <1% | 319 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 958 | $1K |
| 83993 | <1% | 65 | $1K | |
| 82784 | <1% | 60 | $1K | |
| 85018 | <1% | 556 | $1K | |
| 80329 | <1% | 987 | $1K | |
| 80197 | <1% | 84 | $1K | |
| 83935 | <1% | 359 | $1K | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 820 | $1K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 607 | $1K |
| 84155 | <1% | 269 | $1K | |
| 74022 | <1% | 25 | $999.95 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 249 | $936.25 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 663 | $931.42 |
| 80324 | <1% | 1,036 | $930.49 | |
| 80359 | <1% | 1,060 | $922.97 | |
| 73600 | <1% | 14 | $903.00 | |
| 73552 | <1% | 12 | $885.99 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 71 | $846.91 |
| 86677 | <1% | 132 | $843.30 | |
| 83930 | <1% | 261 | $831.36 | |
| 85384 | <1% | 205 | $810.99 | |
| 82805 | <1% | 74 | $775.10 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 14 | $722.75 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 413 | $717.99 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,384 | $701.77 |
| 86769 | <1% | 70 | $699.91 | |
| 80320 | <1% | 1,205 | $693.26 | |
| 89051 | <1% | 102 | $646.49 | |
| 87149 | <1% | 252 | $624.92 | |
| 12011 | <1% | 73 | $573.38 | |
| 85046 | <1% | 148 | $558.35 | |
| 88304 | <1% | 378 | $544.80 | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 31 | $500.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 275 | $487.44 |
| 80202 | <1% | 63 | $466.33 | |
| 12001 | <1% | 51 | $462.60 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 175 | $446.62 |
| 84134 | <1% | 104 | $374.11 | |
| 82950 | <1% | 93 | $368.64 | |
| 82951 | <1% | 26 | $363.00 | |
| 85045 | <1% | 149 | $348.84 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 48 | $301.45 |
| 86140 | <1% | 512 | $274.91 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 144 | $259.86 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 381 | $245.36 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 300 | $241.78 |
| 83002 | <1% | 12 | $241.38 | |
| 82465 | <1% | 87 | $225.48 | |
| 90756 | <1% | 36 | $225.12 | |
| 84478 | <1% | 93 | $220.23 | |
| 83021 | <1% | 12 | $219.00 | |
| 80185 | <1% | 40 | $217.87 | |
| 90749 | <1% | 282 | $211.17 | |
| 83718 | <1% | 46 | $204.00 | |
| 82533 | <1% | 18 | $197.98 | |
| 29125 | <1% | 37 | $196.47 | |
| 92610 | <1% | 13 | $173.93 | |
| 87807 | <1% | 71 | $169.29 | |
| 86709 | <1% | 26 | $155.64 | |
| 82378 | <1% | 12 | $146.00 | |
| 88307 | <1% | 34 | $127.53 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 55 | $127.00 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 884 | $124.41 |
| 86225 | <1% | 26 | $108.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 160 | $106.98 |
| 82390 | <1% | 13 | $103.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 375 | $88.80 |
| 82705 | <1% | 14 | $77.00 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 26 | $74.52 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,327 | $74.12 |
| 90688 | <1% | 36 | $68.19 | |
| 82150 | <1% | 12 | $67.00 | |
| 82952 | <1% | 14 | $64.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 60 | $62.42 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 50 | $55.84 |
| 0272 | <1% | 179 | $53.33 | |
| 87184 | <1% | 16 | $47.00 | |
| 83090 | <1% | 12 | $45.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 29 | $44.10 |
| C1769 | Guide wire | <1% | 43 | $42.81 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 28 | $19.66 |
| 12002 | <1% | 12 | $12.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 112 | $8.58 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 12 | $4.77 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 23 | $3.95 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 15 | $2.42 |
| 0320 | 0% | 21 | $0.00 | |
| 0302 | 0% | 17 | $0.00 | |
| 0301 | 0% | 94 | $0.00 | |
| 3044F | 0% | 670 | $0.00 | |
| 0305 | 0% | 52 | $0.00 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 12 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWINNIK, MITCHELL (SENIOR VICE PRESIDENT/AREA MANAGER)